Spinal cord malignant astrocytomas: Clinicopathologic features in 36 cases
Malignant astrocytomas of the spinal cord are uncommon neoplasms with a dismal prognosis. To the authors' knowledge, little information has been published to date regarding the prognostic impact of clinicopathologic factors. The authors studied 36 cases to investigate the prognostic effect of t...
Gespeichert in:
| Veröffentlicht in: | Cancer 2003-08, Vol.98 (3), p.554-561 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 561 |
|---|---|
| container_issue | 3 |
| container_start_page | 554 |
| container_title | Cancer |
| container_volume | 98 |
| creator | SANTI, Mariarita MENA, Hernando WONG, Kondi KOELLER, Kelly OLSEN, Cara RUSHING, Elisabeth J |
| description | Malignant astrocytomas of the spinal cord are uncommon neoplasms with a dismal prognosis. To the authors' knowledge, little information has been published to date regarding the prognostic impact of clinicopathologic factors.
The authors studied 36 cases to investigate the prognostic effect of the World Health Organization (WHO) tumor grade, tumor localization, cell proliferative activity, p53 expression, and therapy.
Sixteen patients (44%) underwent biopsy alone, 11 (31%) underwent subtotal resection, and 7 (19%) underwent macroscopic total excision. For two patients, there were no data available regarding surgical treatment. Among the 36 patients (mean age, 32.4 years), there were 23 males (63%) and 13 (36%) females. Their initial biopsies showed 21 (63%) glioblastoma multiforme (GBM) cases (WHO Grade 4), 13 (36%) anaplastic astrocytomas (AA) (WHO Grade 3), and 2 (6%) astrocytomas (A) (WHO Grade 2). After initial surgery, 10 (29%) patients were treated with radiation therapy alone and 7 (19%) received radiation therapy with chemotherapy. Patterns of disease recurrence included extraneural metastases (two cases), brain metastases (five cases), local extension (one case), and diffuse spread along the neuraxis (six cases). Two A (100%) and six AA (46%) cases progressed to GBM. The overall median survival time was 33 months (range, 24-42 months) for A, 10 months (range, 1-84 months) for AA, and 10 months (range, 1-43 months) for GBM.
Patients older than 40 years have a shorter survival period compared with younger patients. There is a high risk of central nervous system dissemination in patients with this disease. |
| doi_str_mv | 10.1002/cncr.11514 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73565432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73565432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c303t-5b22ceadac45850909b22f31d8d5b7e605b3433fb945c565e00fc43c21171d843</originalsourceid><addsrcrecordid>eNqF0D1PwzAQBmALgWgpLPwAlAUGpJTzVz7YUMWnKjEAElvkXJxi5MTFTob-e1IaqSPT6U7PvcNLyDmFOQVgN9iin1MqqTggUwp5GgMV7JBMASCLpeCfE3ISwvewpkzyYzKhLEtzkfIpeXlbm1bZCJ2vokZZs2pV20UqdN7hpnONCrfRwprWoFur7stZtzIY1Vp1vdchMm3EkwhV0OGUHNXKBn02zhn5eLh_XzzFy9fH58XdMkYOvItlyRhqVSkUMpOQQz4cak6rrJJlqhOQJRec12UuJMpEaoAaBUdGaTogwWfkape79u6n16ErGhNQW6ta7fpQpHz4Epz9CxkkTKbJNvF6B9G7ELyui7U3jfKbgkKxrbjYVlz8VTzgizG1Lxtd7enY6QAuR6ACKlt71aIJeyfyhIkc-C8I4IM3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20625764</pqid></control><display><type>article</type><title>Spinal cord malignant astrocytomas: Clinicopathologic features in 36 cases</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>SANTI, Mariarita ; MENA, Hernando ; WONG, Kondi ; KOELLER, Kelly ; OLSEN, Cara ; RUSHING, Elisabeth J</creator><creatorcontrib>SANTI, Mariarita ; MENA, Hernando ; WONG, Kondi ; KOELLER, Kelly ; OLSEN, Cara ; RUSHING, Elisabeth J</creatorcontrib><description>Malignant astrocytomas of the spinal cord are uncommon neoplasms with a dismal prognosis. To the authors' knowledge, little information has been published to date regarding the prognostic impact of clinicopathologic factors.
The authors studied 36 cases to investigate the prognostic effect of the World Health Organization (WHO) tumor grade, tumor localization, cell proliferative activity, p53 expression, and therapy.
Sixteen patients (44%) underwent biopsy alone, 11 (31%) underwent subtotal resection, and 7 (19%) underwent macroscopic total excision. For two patients, there were no data available regarding surgical treatment. Among the 36 patients (mean age, 32.4 years), there were 23 males (63%) and 13 (36%) females. Their initial biopsies showed 21 (63%) glioblastoma multiforme (GBM) cases (WHO Grade 4), 13 (36%) anaplastic astrocytomas (AA) (WHO Grade 3), and 2 (6%) astrocytomas (A) (WHO Grade 2). After initial surgery, 10 (29%) patients were treated with radiation therapy alone and 7 (19%) received radiation therapy with chemotherapy. Patterns of disease recurrence included extraneural metastases (two cases), brain metastases (five cases), local extension (one case), and diffuse spread along the neuraxis (six cases). Two A (100%) and six AA (46%) cases progressed to GBM. The overall median survival time was 33 months (range, 24-42 months) for A, 10 months (range, 1-84 months) for AA, and 10 months (range, 1-43 months) for GBM.
Patients older than 40 years have a shorter survival period compared with younger patients. There is a high risk of central nervous system dissemination in patients with this disease.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.11514</identifier><identifier>PMID: 12879473</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York, NY: Wiley-Liss</publisher><subject>Adolescent ; Adult ; Age Distribution ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Astrocytoma - classification ; Astrocytoma - metabolism ; Astrocytoma - pathology ; Astrocytoma - therapy ; Biological and medical sciences ; Cell Division ; Child ; Child, Preschool ; Combined Modality Therapy ; Female ; Humans ; Immunoenzyme Techniques ; Ki-67 Antigen - metabolism ; Male ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Neurology ; Prognosis ; Radiotherapy Dosage ; Spinal Cord Neoplasms - classification ; Spinal Cord Neoplasms - metabolism ; Spinal Cord Neoplasms - pathology ; Spinal Cord Neoplasms - therapy ; Survival Rate ; Treatment Outcome ; Tumor Suppressor Protein p53 - metabolism ; Tumors of the nervous system. Phacomatoses</subject><ispartof>Cancer, 2003-08, Vol.98 (3), p.554-561</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11514</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c303t-5b22ceadac45850909b22f31d8d5b7e605b3433fb945c565e00fc43c21171d843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14962490$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12879473$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SANTI, Mariarita</creatorcontrib><creatorcontrib>MENA, Hernando</creatorcontrib><creatorcontrib>WONG, Kondi</creatorcontrib><creatorcontrib>KOELLER, Kelly</creatorcontrib><creatorcontrib>OLSEN, Cara</creatorcontrib><creatorcontrib>RUSHING, Elisabeth J</creatorcontrib><title>Spinal cord malignant astrocytomas: Clinicopathologic features in 36 cases</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Malignant astrocytomas of the spinal cord are uncommon neoplasms with a dismal prognosis. To the authors' knowledge, little information has been published to date regarding the prognostic impact of clinicopathologic factors.
The authors studied 36 cases to investigate the prognostic effect of the World Health Organization (WHO) tumor grade, tumor localization, cell proliferative activity, p53 expression, and therapy.
Sixteen patients (44%) underwent biopsy alone, 11 (31%) underwent subtotal resection, and 7 (19%) underwent macroscopic total excision. For two patients, there were no data available regarding surgical treatment. Among the 36 patients (mean age, 32.4 years), there were 23 males (63%) and 13 (36%) females. Their initial biopsies showed 21 (63%) glioblastoma multiforme (GBM) cases (WHO Grade 4), 13 (36%) anaplastic astrocytomas (AA) (WHO Grade 3), and 2 (6%) astrocytomas (A) (WHO Grade 2). After initial surgery, 10 (29%) patients were treated with radiation therapy alone and 7 (19%) received radiation therapy with chemotherapy. Patterns of disease recurrence included extraneural metastases (two cases), brain metastases (five cases), local extension (one case), and diffuse spread along the neuraxis (six cases). Two A (100%) and six AA (46%) cases progressed to GBM. The overall median survival time was 33 months (range, 24-42 months) for A, 10 months (range, 1-84 months) for AA, and 10 months (range, 1-43 months) for GBM.
Patients older than 40 years have a shorter survival period compared with younger patients. There is a high risk of central nervous system dissemination in patients with this disease.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Distribution</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Astrocytoma - classification</subject><subject>Astrocytoma - metabolism</subject><subject>Astrocytoma - pathology</subject><subject>Astrocytoma - therapy</subject><subject>Biological and medical sciences</subject><subject>Cell Division</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Ki-67 Antigen - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Neurology</subject><subject>Prognosis</subject><subject>Radiotherapy Dosage</subject><subject>Spinal Cord Neoplasms - classification</subject><subject>Spinal Cord Neoplasms - metabolism</subject><subject>Spinal Cord Neoplasms - pathology</subject><subject>Spinal Cord Neoplasms - therapy</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Tumors of the nervous system. Phacomatoses</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0D1PwzAQBmALgWgpLPwAlAUGpJTzVz7YUMWnKjEAElvkXJxi5MTFTob-e1IaqSPT6U7PvcNLyDmFOQVgN9iin1MqqTggUwp5GgMV7JBMASCLpeCfE3ISwvewpkzyYzKhLEtzkfIpeXlbm1bZCJ2vokZZs2pV20UqdN7hpnONCrfRwprWoFur7stZtzIY1Vp1vdchMm3EkwhV0OGUHNXKBn02zhn5eLh_XzzFy9fH58XdMkYOvItlyRhqVSkUMpOQQz4cak6rrJJlqhOQJRec12UuJMpEaoAaBUdGaTogwWfkape79u6n16ErGhNQW6ta7fpQpHz4Epz9CxkkTKbJNvF6B9G7ELyui7U3jfKbgkKxrbjYVlz8VTzgizG1Lxtd7enY6QAuR6ACKlt71aIJeyfyhIkc-C8I4IM3</recordid><startdate>20030801</startdate><enddate>20030801</enddate><creator>SANTI, Mariarita</creator><creator>MENA, Hernando</creator><creator>WONG, Kondi</creator><creator>KOELLER, Kelly</creator><creator>OLSEN, Cara</creator><creator>RUSHING, Elisabeth J</creator><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20030801</creationdate><title>Spinal cord malignant astrocytomas: Clinicopathologic features in 36 cases</title><author>SANTI, Mariarita ; MENA, Hernando ; WONG, Kondi ; KOELLER, Kelly ; OLSEN, Cara ; RUSHING, Elisabeth J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c303t-5b22ceadac45850909b22f31d8d5b7e605b3433fb945c565e00fc43c21171d843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Distribution</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Astrocytoma - classification</topic><topic>Astrocytoma - metabolism</topic><topic>Astrocytoma - pathology</topic><topic>Astrocytoma - therapy</topic><topic>Biological and medical sciences</topic><topic>Cell Division</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Ki-67 Antigen - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Neurology</topic><topic>Prognosis</topic><topic>Radiotherapy Dosage</topic><topic>Spinal Cord Neoplasms - classification</topic><topic>Spinal Cord Neoplasms - metabolism</topic><topic>Spinal Cord Neoplasms - pathology</topic><topic>Spinal Cord Neoplasms - therapy</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Tumors of the nervous system. Phacomatoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SANTI, Mariarita</creatorcontrib><creatorcontrib>MENA, Hernando</creatorcontrib><creatorcontrib>WONG, Kondi</creatorcontrib><creatorcontrib>KOELLER, Kelly</creatorcontrib><creatorcontrib>OLSEN, Cara</creatorcontrib><creatorcontrib>RUSHING, Elisabeth J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SANTI, Mariarita</au><au>MENA, Hernando</au><au>WONG, Kondi</au><au>KOELLER, Kelly</au><au>OLSEN, Cara</au><au>RUSHING, Elisabeth J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spinal cord malignant astrocytomas: Clinicopathologic features in 36 cases</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2003-08-01</date><risdate>2003</risdate><volume>98</volume><issue>3</issue><spage>554</spage><epage>561</epage><pages>554-561</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>Malignant astrocytomas of the spinal cord are uncommon neoplasms with a dismal prognosis. To the authors' knowledge, little information has been published to date regarding the prognostic impact of clinicopathologic factors.
The authors studied 36 cases to investigate the prognostic effect of the World Health Organization (WHO) tumor grade, tumor localization, cell proliferative activity, p53 expression, and therapy.
Sixteen patients (44%) underwent biopsy alone, 11 (31%) underwent subtotal resection, and 7 (19%) underwent macroscopic total excision. For two patients, there were no data available regarding surgical treatment. Among the 36 patients (mean age, 32.4 years), there were 23 males (63%) and 13 (36%) females. Their initial biopsies showed 21 (63%) glioblastoma multiforme (GBM) cases (WHO Grade 4), 13 (36%) anaplastic astrocytomas (AA) (WHO Grade 3), and 2 (6%) astrocytomas (A) (WHO Grade 2). After initial surgery, 10 (29%) patients were treated with radiation therapy alone and 7 (19%) received radiation therapy with chemotherapy. Patterns of disease recurrence included extraneural metastases (two cases), brain metastases (five cases), local extension (one case), and diffuse spread along the neuraxis (six cases). Two A (100%) and six AA (46%) cases progressed to GBM. The overall median survival time was 33 months (range, 24-42 months) for A, 10 months (range, 1-84 months) for AA, and 10 months (range, 1-43 months) for GBM.
Patients older than 40 years have a shorter survival period compared with younger patients. There is a high risk of central nervous system dissemination in patients with this disease.</abstract><cop>New York, NY</cop><pub>Wiley-Liss</pub><pmid>12879473</pmid><doi>10.1002/cncr.11514</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2003-08, Vol.98 (3), p.554-561 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73565432 |
| source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection |
| subjects | Adolescent Adult Age Distribution Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Astrocytoma - classification Astrocytoma - metabolism Astrocytoma - pathology Astrocytoma - therapy Biological and medical sciences Cell Division Child Child, Preschool Combined Modality Therapy Female Humans Immunoenzyme Techniques Ki-67 Antigen - metabolism Male Medical sciences Middle Aged Neoplasm Recurrence, Local - pathology Neoplasm Staging Neurology Prognosis Radiotherapy Dosage Spinal Cord Neoplasms - classification Spinal Cord Neoplasms - metabolism Spinal Cord Neoplasms - pathology Spinal Cord Neoplasms - therapy Survival Rate Treatment Outcome Tumor Suppressor Protein p53 - metabolism Tumors of the nervous system. Phacomatoses |
| title | Spinal cord malignant astrocytomas: Clinicopathologic features in 36 cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T09%3A49%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spinal%20cord%20malignant%20astrocytomas:%20Clinicopathologic%20features%20in%2036%20cases&rft.jtitle=Cancer&rft.au=SANTI,%20Mariarita&rft.date=2003-08-01&rft.volume=98&rft.issue=3&rft.spage=554&rft.epage=561&rft.pages=554-561&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.11514&rft_dat=%3Cproquest_cross%3E73565432%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20625764&rft_id=info:pmid/12879473&rfr_iscdi=true |